Drug Profile

BT 01001

Alternative Names: BT-01001

Latest Information Update: 08 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beyang Therapeutics
Class Small molecules
Mechanism of Action Fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Aug 2025 Preclinical trials in Diabetic neuropathies in China (Ophthalmic) before August 2025 (Beyang Therapeutics pipeline, August 2025)
28 Jul 2025 USFDA approves IND application for BT 01001 in Diabetic neuropathies (Beyang Therapeutics pipeline, August 2025)
05 Mar 2025 Beyang Therapeutics plans a phase I trial for Diabetic neuropathies (In Volunteers) (Beyang Therapeutics pipeline, July 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com